RTW Investments LP has recently announced that it has increased stake in Immunocore Holdings plc (NASDAQ:IMCR) by 11.39%. After grabbing 4.45 million shares, the institutional investor is now in possession of 0.46 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.83% having worth around $279.6 million. Moreover, Rock Springs Capital Management L increased its share by 0.82 million to have a control over 3.49 million shares. And Baker Bros. Advisors LP raised its holdings to 1.0 shares by acquiring 2.52 million shares or 5.56% of the stake.
Immunocore Holdings plc (IMCR) concluded trading on 01/11/23 at a closing price of $56.91, with 0.76 million shares of worth about $43.45 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 30.71% during that period and on Wednesday the price saw a gain of about 4.35%. Currently the company’s common shares owned by public are about 47.00M shares, out of which, 30.52M shares are available for trading.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $76.37 and could fall to a lowest price of $53.96. The stock’s current price level is 27.5% above of average price target set by the analysts, while a rise to estimated low would result in loss of -5.47% for the stock. However, touching the estimated high of $76.37 would mean a gain of 25.48% for the stock.
T Rowe Price Health Sciences Fund, Wellington Mgmt. Funds, and Fidelity Small Cap Growth Fund are the top 3 mutual funds which are holding stakes in Immunocore Holdings plc T Rowe Price Health Sciences Fund is currently holding 0.92 million shares of worth totaling $57.75 million. The company recently came buying 0.69 million shares which brought its stake up to 2.03% of the company’s outstanding shares. Wellington Mgmt. Funds sold -0.18 million shares, after which its hold over company’s outstanding shares shrunk to 1.12%, leaving 0.51 million shares with the mutual fund that have a worth of about $31.95 million. Fidelity Small Cap Growth Fund, after selling 0.32 million shares, have now control over 0.70% of the stake in the company. It holds 85.0 shares of worth $20.0 million.
Immunocore Holdings plc (NASDAQ: IMCR) started trading at $54.60, above $0.06 from concluding price of the previous day. However, the stock later moved at a day high price of 57.20, or with a gain of 4.35%. Stock saw a price change of 4.61% in past 5 days and over the past one month there was a price change of -6.83%. Year-to-date (YTD), IMCR shares are showing a performance of -0.28% which increased to 101.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.43 but also hit the highest price of $69.06 during that period. The average intraday trading volume for Immunocore Holdings plc shares is 386.89K. The stock is currently trading 0.50% above its 20-day simple moving average (SMA20), while that difference is down -3.03% for SMA50 and it goes to 25.35% higher than SMA200.
RTW Investments LP acquired 4.45 million shares of Immunocore Holdings plc having value of about $279.6 million. Data submitted at the U.S SEC by RTW Investments LP revealed that the firm now holds 0.46 million shares in the company valued at close to $25912773.39, or have control over 11.39% stake in the company. Immunocore Holdings plc (NASDAQ: IMCR) currently have 47.00M outstanding shares and institutions hold larger chunk of about 58.90% of that. Holding of mutual funds in the company is about 10.71% while other institutional holders and individual stake holders have control over 45.37% and — of the stake respectively.
The stock has a current market capitalization of $2.51B. It has posted earnings per share of -$1.53 in the same period. It has Quick Ratio of 5.20 while making debt-to-equity ratio of 0.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMCR, volatility over the week remained 7.87% while standing at 5.05% over the month.
Analysts are in expectations that Immunocore Holdings plc (IMCR) stock would likely to be making an EPS of -$0.43 in the current quarter, while forecast for next quarter EPS is -$0.49 and it is -$1.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.79 which is -$0.12 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$69 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -76.70% while it is estimated to decrease by -28.40% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 16, 2022 offering a Buy rating for the stock and assigned a target price range of between $33 and $80 to it. Coverage by Barclays stated Immunocore Holdings plc (IMCR) stock as an Overweight in their note to investors on November 30, 2022, suggesting a price target of $80 for the stock. On September 09, 2022, Morgan Stanley Initiated their recommendations, while on September 08, 2022, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $82. Stock get an Outperform rating from Cowen on August 08, 2022.
